Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

not_yet_recruiting267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

NCT07477808
recruitingphase_2

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

NCT07022002
not_yet_recruitingphase_3

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

NCT06828757

Clinical Trials (3)

Showing 3 of 3 trials
NCT07477808Phase 3

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT07022002Phase 2

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Recruiting
NCT06828757Phase 3

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3